DE69326967D1 - Phasenmodulationsenergieübertragungsfluoroimmunassay - Google Patents

Phasenmodulationsenergieübertragungsfluoroimmunassay

Info

Publication number
DE69326967D1
DE69326967D1 DE69326967T DE69326967T DE69326967D1 DE 69326967 D1 DE69326967 D1 DE 69326967D1 DE 69326967 T DE69326967 T DE 69326967T DE 69326967 T DE69326967 T DE 69326967T DE 69326967 D1 DE69326967 D1 DE 69326967D1
Authority
DE
Germany
Prior art keywords
fluoroimmunoassay
energy transfer
phase modulation
modulation energy
phase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69326967T
Other languages
English (en)
Other versions
DE69326967T2 (de
Inventor
Joseph Lakowicz
Badri Maliwal
Richard Thompson
Alvydas Ozinskas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE69326967D1 publication Critical patent/DE69326967D1/de
Publication of DE69326967T2 publication Critical patent/DE69326967T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6408—Fluorescence; Phosphorescence with measurement of decay time, time resolved fluorescence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G01N2021/6439—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks
    • G01N2021/6441—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks with two or more labels
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/80—Fluorescent dyes, e.g. rhodamine
DE69326967T 1992-01-17 1993-01-15 Phasenmodulationsenergieübertragungsfluoroimmunassay Expired - Fee Related DE69326967T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82223392A 1992-01-17 1992-01-17

Publications (2)

Publication Number Publication Date
DE69326967D1 true DE69326967D1 (de) 1999-12-16
DE69326967T2 DE69326967T2 (de) 2000-06-15

Family

ID=25235520

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69326967T Expired - Fee Related DE69326967T2 (de) 1992-01-17 1993-01-15 Phasenmodulationsenergieübertragungsfluoroimmunassay

Country Status (5)

Country Link
US (1) US5631169A (de)
EP (1) EP0552108B1 (de)
JP (1) JP3325939B2 (de)
CA (1) CA2087413A1 (de)
DE (1) DE69326967T2 (de)

Families Citing this family (210)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997007402A1 (en) * 1995-08-17 1997-02-27 The Ontario Cancer Institute Protein fibril assembly assay
US5800996A (en) * 1996-05-03 1998-09-01 The Perkin Elmer Corporation Energy transfer dyes with enchanced fluorescence
AT405103B (de) * 1996-10-16 1999-05-25 Avl Verbrennungskraft Messtech Sensorschicht zur quantitativen bestimmung zumindest einer chemischen komponente einer gasförmigen oder flüssigen probe
ES2278399T3 (es) * 1996-11-20 2007-08-01 Introgen Therapeutics, Inc. Metodo mejorado para la produccion y purificacion de vectores adenovirales.
FR2763944B1 (fr) * 1997-06-03 2000-12-15 Centre Nat Rech Scient Nouveaux derives de coumarines, leurs procedes de preparation et leur application comme medicaments en tant qu'inhibiteurs de proteases
FR2764387B1 (fr) * 1997-06-05 1999-07-23 Centre Nat Rech Scient Utilisation d'une proteine fluorescente pour la detection d'interactions entre une proteine cible et son ligand
US7745142B2 (en) 1997-09-15 2010-06-29 Molecular Devices Corporation Molecular modification assays
US6297018B1 (en) 1998-04-17 2001-10-02 Ljl Biosystems, Inc. Methods and apparatus for detecting nucleic acid polymorphisms
AU1366299A (en) * 1997-10-27 1999-05-17 Boston Probes, Inc. Methods, kits and compositions pertaining to pna molecular beacons
US6485901B1 (en) 1997-10-27 2002-11-26 Boston Probes, Inc. Methods, kits and compositions pertaining to linear beacons
US6214628B1 (en) * 1998-01-14 2001-04-10 Joseph R. Lakowicz Method of conducting an assay of a sample containing an analyte of interest
WO1999049293A2 (en) 1998-03-24 1999-09-30 Boston Probes, Inc. Methods, kits and compositions pertaining to detection complexes
GB9811483D0 (en) * 1998-05-29 1998-07-29 Photonic Research Systems Limi Luminescence assay using cyclical excitation wavelength sequence
EP1102990B1 (de) * 1998-07-08 2003-09-17 The Victoria University of Manchester Probenanalyse
US5998146A (en) * 1998-07-17 1999-12-07 Wallac Oy Homogeneous luminescence assay method based on energy transfer
US6806089B1 (en) * 1998-09-08 2004-10-19 University Of Maryland, Baltimore Low frequency modulation sensors using nanosecond fluorophores
US6708060B1 (en) * 1998-11-09 2004-03-16 Transpharma Ltd. Handheld apparatus and method for transdermal drug delivery and analyte extraction
US6611706B2 (en) 1998-11-09 2003-08-26 Transpharma Ltd. Monopolar and bipolar current application for transdermal drug delivery and analyte extraction
US6597946B2 (en) * 1998-11-09 2003-07-22 Transpharma Ltd. Electronic card for transdermal drug delivery and analyte extraction
US6148232A (en) 1998-11-09 2000-11-14 Elecsys Ltd. Transdermal drug delivery and analyte extraction
WO2000028327A1 (en) * 1998-11-11 2000-05-18 University Of Maryland Baltimore Anisotropy based sensing
US7166475B2 (en) * 1999-02-26 2007-01-23 Cyclacel Ltd. Compositions and methods for monitoring the modification state of a pair of polypeptides
US6410255B1 (en) * 1999-05-05 2002-06-25 Aurora Biosciences Corporation Optical probes and assays
ES2367551T3 (es) * 1999-08-13 2011-11-04 Bayer Technology Services Gmbh Dispositivo y procedimiento para la determinación de múltiples analitos.
GB9926336D0 (en) * 1999-11-05 2000-01-12 Isis Innovation Universal flourescent sensors
AU2001243345A1 (en) 2000-02-29 2001-09-12 Millennium Pharmaceuticals, Inc. 1983, 52881, 2398, 45449, 50289, and 52872, g protein-coupled receptors and uses therefor
DE60142356D1 (de) 2000-07-18 2010-07-22 Millennium Pharm Inc 18480 humane proteinkinasemoleküle und ihre verwendungen
US7109043B2 (en) * 2000-07-28 2006-09-19 Japan Science And Technology Corporation Fluorescent probe for magnesium ion determination
US20080194022A1 (en) * 2000-08-03 2008-08-14 Clarke Michael F Isolation and use of solid tumor stem cells
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US6447995B1 (en) 2000-10-04 2002-09-10 Genvec, Inc. Utilizing intrinsic fluorescence to detect adenovirus
AU2002230419A1 (en) * 2000-11-08 2002-05-21 Science And Technology Corporation @Unm Fluorescence and fret based assays for biomolecules on beads
WO2002040998A2 (de) * 2000-11-17 2002-05-23 Zeptosens Ag Kit und verfahren zur multianalytbestimmung
US6939721B2 (en) * 2000-12-18 2005-09-06 Agilent Technologies, Inc. Fluorescence immunoassays using organo-metallic complexes for energy transfer
GB0113435D0 (en) 2001-06-04 2001-07-25 Amersham Pharm Biotech Uk Ltd Acridone derivatives as labels for fluorescence detection of target materials
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20060068405A1 (en) * 2004-01-27 2006-03-30 Alex Diber Methods and systems for annotating biomolecular sequences
EP1455815A4 (de) * 2001-12-19 2006-11-02 Millennium Pharm Inc Mitglieder der familie der humanen diacylglycerol-acyltransferase 2 (dgat2) und ihre verwendung
US20030165954A1 (en) 2002-01-09 2003-09-04 Third Wave Technologies, Inc. Cancer profiles
DE10212960A1 (de) * 2002-03-22 2003-10-23 Gnothis Holding Sa Ecublens Verwendung von Oxazin-Farbstoffen als Markierungsgruppen für die Einzelmolekülanalyse
EP1499255B1 (de) * 2002-04-19 2015-07-22 Syneron Medical Ltd. In der hand gehaltene transdermale arzneimittelabgabe und analytenextraktion
US20030224354A1 (en) * 2002-05-30 2003-12-04 Introgen Therapeutics Inc. Quantifying viral particles with intrinsic fluorescence
EP1523496B1 (de) * 2002-07-18 2011-06-29 Merus B.V. Rekombinante Produktion von Antikörpermischungen
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US7217518B2 (en) * 2002-08-02 2007-05-15 Applera Corporation Fluorescence polarization assay
EP2311980A1 (de) 2002-08-20 2011-04-20 Millennium Pharmaceuticals, Inc. Zusammensetzungen, Kits und Verfahren zur Identifizierung, Beurteilung, Vorbeugung und Therapie von Gebärmutterhalskrebs
AU2003293013A1 (en) * 2002-11-21 2004-06-18 University Of Massachusets Diagnosing and treating hematopoietic cancers
JP2006510357A (ja) * 2002-11-22 2006-03-30 ザ ジョーンズ ホプキンズ ユニバーシティ 認識障害の処置のための標的
EP2112229A3 (de) 2002-11-25 2009-12-02 Sequenom, Inc. Verfahren zum Identifizieren des Brustkrebsrisikos und zugehörige Behandlungen
ES2542328T3 (es) 2002-12-06 2015-08-04 Millennium Pharmaceuticals, Inc. Métodos para la identificación, evaluación y tratamiento de pacientes con terapia de inhibición del proteasoma
TWI247116B (en) * 2003-01-17 2006-01-11 Far East Bio Tec Co Ltd Fluorescent labeling reagent and its kit using B-phycoerythrin (B-PE) and its derivatives
JP4553895B2 (ja) * 2003-03-28 2010-09-29 ソウッカ、テロ 均質発光エネルギー伝達バイオアッセイ
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
CA2528669A1 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
DE10330213A1 (de) 2003-07-03 2005-02-17 Ludwig Prof. Dr.med. Neyses Verwendung von Inhibitoren der Plasmamembran-Calcium-Atpase (PMCA) zur Hemmung der Spermienmobilität
CA2445420A1 (en) * 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
US7727752B2 (en) * 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
US7619059B2 (en) * 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
WO2005014796A2 (en) 2003-08-08 2005-02-17 Invitrogen Corporation Methods and compositions for seamless cloning of nucleic acid molecules
EP1660870A2 (de) 2003-08-26 2006-05-31 Blueshift Biotechnologies, Inc. Zeitabhängige fluoreszenzmessungen
JP2007505315A (ja) * 2003-09-12 2007-03-08 インヴィトロジェン コーポレーション 多重結合および活性アッセイ
MXPA06003402A (es) 2003-10-07 2006-06-27 Millennium Pharm Inc Moleculas de acidos nucleicos y proteinas para la identificacion, evaluacion, prevencion y tratamiento de cancer de ovario.
EP1697534B1 (de) 2003-12-01 2010-06-02 Life Technologies Corporation Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon
JP5912211B2 (ja) * 2004-01-20 2016-04-27 メルス ビー．ヴィー． 結合タンパク質の混合物
AU2005206389A1 (en) * 2004-01-27 2005-08-04 Compugen Ltd. Methods of identifying putative gene products by interspecies sequence comparison and biomolecular sequences uncovered thereby
US20050232927A1 (en) * 2004-02-03 2005-10-20 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
WO2005081801A2 (en) * 2004-02-09 2005-09-09 Blueshift Biotechnologies, Inc. Methods and apparatus for scanning small sample volumes
TW200540422A (en) * 2004-04-16 2005-12-16 Wyeth Corp A novel method for determination of human plasma plasminogen activator inhibitor
US7563891B2 (en) * 2004-05-21 2009-07-21 Becton, Dickinson & Company Long wavelength thiol-reactive fluorophores
EP1766015A4 (de) * 2004-06-09 2008-10-01 Univ Mcgill Für acetylcholin-gesteuerte chloridkanal-untereinheiten aus caenorhabditis elegans codierende polynukleotide
US7858323B2 (en) 2004-06-09 2010-12-28 The Regents Of The University Of Michigan Phage microarray profiling of the humoral response to disease
EP1774024A4 (de) * 2004-07-02 2012-04-04 Blueshift Biotechnologies Inc Erforschung von fluorophor-mikroumgebungen
WO2006135886A2 (en) * 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
AU2006259583A1 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1917347B1 (de) 2005-08-22 2015-10-07 Cornell Research Foundation, Inc. Zusammensetzungen und verfahren zur analyse von proteinwechselwirkungen
US9957569B2 (en) * 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
CA2622295C (en) 2005-09-12 2019-01-15 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
ES2374450T3 (es) 2005-09-20 2012-02-16 OSI Pharmaceuticals, LLC Marcadores biológicos predictivos de respuesta anticancerígena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina.
US8652467B2 (en) * 2005-10-14 2014-02-18 The Regents Of The University Of Michigan Dek protein compositions and methods of using the same
EP1777523A1 (de) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) In-vitro-Verfahren zur Prognose einer Tumorprogression und des Ergebnisses bei einem Patienten sowie Mittel zur Durchführung dieses Verfahrens
US20090175845A1 (en) * 2005-10-25 2009-07-09 The Trustees Of Columbia University In The City Of New York Methods for identifying compounds that modulate phb domain protein activity and compositions thereof
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
WO2007053577A2 (en) 2005-10-31 2007-05-10 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
AU2006308847C1 (en) * 2005-10-31 2012-05-10 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
US20090291437A1 (en) * 2005-11-02 2009-11-26 O'brien Sean Methods for targeting quadruplex sequences
EP2368912B1 (de) 2006-01-05 2017-05-03 Children's Medical Center Corporation Regulatoren von NFAT
WO2008121102A2 (en) * 2006-02-21 2008-10-09 The Regents Of The University Of Michigan Hedgehog signaling pathway antagonist cancer treatment
AU2007257162A1 (en) 2006-06-05 2007-12-13 Cancer Care Ontario Assessment of risk for colorectal cancer
EP2067041A2 (de) 2006-10-03 2009-06-10 Biogen Idec MA, Inc. Biomarker und testreihen zur behandlung von krebs
US20100136537A1 (en) * 2006-10-10 2010-06-03 The Regents Of The University Of Michigan Photoreceptor precursor cells
JP4965963B2 (ja) * 2006-10-16 2012-07-04 セイコーインスツル株式会社 蛍光性化合物及びタンパク質のトポロジー解析方法
EP2727965B1 (de) 2006-10-27 2019-03-06 Life Technologies Corporation FLUOROGENE pH-SENSITIVE FARBSTOFFE UND IHRE VERWENDUNG
US8148147B2 (en) * 2007-01-24 2012-04-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
EP1961825A1 (de) 2007-02-26 2008-08-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Verfahren zur Vorhersage des Auftretens von Metastasen bei Brustkrebspatienten
EP2079839A4 (de) 2007-03-05 2009-11-18 Cancer Care Ontario Abschätzung des kolorektalkarzinomrisikos
US8038947B2 (en) * 2007-04-09 2011-10-18 University Of Maryland, Baltimore Analyte sensor devices and holders, and methods and systems utilizing the same
WO2009023059A2 (en) 2007-06-01 2009-02-19 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
US8097422B2 (en) 2007-06-20 2012-01-17 Salk Institute For Biological Studies Kir channel modulators
SI2173379T1 (sl) 2007-07-02 2015-12-31 Oncomed Pharmaceuticals, Inc. Sestavki in postopki za zdravljenje in diagnosticiranje raka
EP2167689B1 (de) 2007-07-06 2012-10-31 The Regents Of The University Of Michigan Wiederkehrende genfusionen bei prostatakrebs
CA2692793C (en) 2007-07-06 2014-05-20 The Regents Of The University Of Michigan Mipol1-etv1 gene rearrangements
WO2009017833A2 (en) 2007-08-02 2009-02-05 Arresto Biosciences Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
US8586081B2 (en) * 2007-09-20 2013-11-19 University Of Massachusetts Detoxified recombinant botulinum neurotoxin
CA2704048A1 (en) 2007-10-29 2009-05-07 Eisai R & D Management Co., Ltd. Methods for prognosing the ability of a zearalenone analog compound to treat cancer
CN101951954A (zh) 2007-11-02 2011-01-19 诺瓦提斯公司 调节低密度脂蛋白受体相关蛋白6(lrp6)的分子和方法
WO2015164330A1 (en) 2014-04-21 2015-10-29 Millennium Pharmaceuticals, Inc. Anti-psyk antibody molecules and use of same for syk-targeted therapy
WO2009092068A1 (en) 2008-01-18 2009-07-23 President And Fellows Of Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
AU2009208607B2 (en) * 2008-01-31 2013-08-01 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
US8709726B2 (en) * 2008-03-11 2014-04-29 Sequenom, Inc. Nucleic acid-based tests for prenatal gender determination
BR122021026834B1 (pt) 2008-04-25 2022-11-08 Takeda Pharmaceutical Company Limited Anticorpos isolados que se ligam a fcrn, composição farmacêutica que compreende os mesmos e métodos para detectar e para modular fcrn
WO2010096036A2 (en) 2008-05-14 2010-08-26 Millennium Pharmaceuticals, Inc. Methods and kits for monitoring the effects of immunomodulators on adaptive immunity
US8476013B2 (en) * 2008-09-16 2013-07-02 Sequenom, Inc. Processes and compositions for methylation-based acid enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
US8962247B2 (en) * 2008-09-16 2015-02-24 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non invasive prenatal diagnoses
TWI506037B (zh) 2008-09-26 2015-11-01 Oncomed Pharm Inc 捲曲結合劑類及彼等之用途
US20100082438A1 (en) * 2008-10-01 2010-04-01 Ronnie Jack Garmon Methods and systems for customer performance scoring
JP2012505900A (ja) 2008-10-14 2012-03-08 ダイアクス コーポレーション 全身性強皮症に伴う肺線維症の治療および予防のためのｉｇｆ−ｉｉ／ｉｇｆ−ｉｉｅ結合タンパク質の使用
CA2779958A1 (en) 2008-11-06 2010-05-14 University Of Miami Role of soluble upar in the pathogenesis of proteinuric kidney disease
US8710104B2 (en) * 2008-11-07 2014-04-29 Triact Therapeutics, Inc. Catecholic butanes and use thereof for cancer therapy
CN104634972B (zh) 2008-11-11 2017-06-13 密执安大学评议会 抗cxcr1组合物和方法
EP2382328A2 (de) 2009-01-09 2011-11-02 The Regents of the University of Michigan Rezidivierende genfusionen bei krebs
US8606366B2 (en) 2009-02-18 2013-12-10 Syneron Medical Ltd. Skin treatment apparatus for personal use and method for using same
US8642834B2 (en) 2009-02-27 2014-02-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401613A2 (de) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Verfahren zur identifizierung von mesenchymähnlichen tumorzellen oder deren bildung hemmenden stoffen
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010118435A2 (en) 2009-04-10 2010-10-14 Tufts Medical Center, Inc. Par-1 activation by metalloproteinase-1 (mmp-1)
WO2010121196A1 (en) 2009-04-16 2010-10-21 Momenta Pharmaceuticals, Inc. Methods of assessing activity of a polysaccharide composition
WO2011011366A2 (en) * 2009-07-20 2011-01-27 Constellation Pharmaceuticals Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
US20110082054A1 (en) 2009-09-14 2011-04-07 Dyax Corp. Libraries of genetic packages comprising novel hc cdr3 designs
AU2010295689B2 (en) 2009-09-17 2014-02-13 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
TWI483736B (zh) 2009-10-23 2015-05-11 Millennium Pharm Inc 抗－ｇｃｃ抗體分子及其相關之組合物及方法
EP2504436A1 (de) 2009-11-23 2012-10-03 INSERM - Institut National de la Santé et de la Recherche Médicale Gegen matrixprotein-1 von typ-a-influenzaviren gerichtete aptamere und ihre verwendungen
EP2516680B1 (de) 2009-12-22 2016-04-06 Sequenom, Inc. Verfahren und kits zur identifizierung von aneuploidie
CA3168591A1 (en) 2010-01-06 2011-07-14 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
WO2011091435A2 (en) 2010-01-25 2011-07-28 Mount Sinai School Of Medicine Methods of treating liver disease
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
TWI518325B (zh) 2010-02-04 2016-01-21 自治醫科大學 對ａｌｋ抑制劑具有先抗性或後抗性癌症的識別、判斷和治療
EP3450979A3 (de) 2010-03-17 2019-04-24 The Regents of The University of Michigan Verwendung von phagenepitopen zur profilierung einer immunreaktion
US20130045871A1 (en) 2010-03-18 2013-02-21 Cornell University Engineering correctly folded antibodies using inner membrane display of twin-arginine translocation intermediates
CN102971337B (zh) 2010-04-01 2016-09-21 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
DE102010019095B4 (de) * 2010-04-30 2016-12-08 Deutsches Zentrum für Luft- und Raumfahrt e.V. Verfahren und Vorrichtung zur Fluoreszenzlebensdauermessung
AU2011281012A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting cardiovascular diseases or conditions
SG10201505723UA (en) 2010-07-23 2015-09-29 Harvard College Methods for detecting signatures of disease or conditions in bodily fluids
AU2011280936A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
WO2012012725A2 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting diseases or conditions using phagocytic cells
US20130266940A1 (en) 2010-07-23 2013-10-10 President And Fellows Of Harvard College Methods of Detecting Kidney-Associated Diseases or Conditions
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
ES2777894T3 (es) 2011-03-02 2020-08-06 Berg Llc Ensayos por interrogación basados en células y usos de los mismos
US20120328567A1 (en) 2011-04-08 2012-12-27 Steven Bushnell Biomarkers predictive of therapeutic responsiveness to ifnb and uses thereof
GB201106395D0 (en) 2011-04-14 2011-06-01 Hubrecht Inst Compounds
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
CN103717750B (zh) 2011-04-29 2017-03-08 塞昆纳姆股份有限公司 少数核酸物质的定量
MX343659B (es) 2011-06-02 2016-11-16 Dyax Corp Proteínas de unión receptoras fc.
CA2846197C (en) 2011-08-23 2024-01-16 Foundation Medicine, Inc. Kif5b-ret fusion molecules and uses thereof
JP6238900B2 (ja) 2011-10-28 2017-11-29 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｎａｅ阻害物質に対する応答のバイオマーカー
EP3492604B1 (de) 2011-11-04 2021-01-06 Gen-Probe Incorporated Molekulartestreagenzien und -verfahren
US9879093B2 (en) 2011-12-20 2018-01-30 Adaerata, Limited Partnershp Single domain antibodies as inhibitors of PCSK9
WO2013113755A1 (en) 2012-01-30 2013-08-08 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Reagents and methods for the treatment of diseases based on the inhibition of calcineurin - nfat signalling pathway
EP4155401A1 (de) 2012-03-02 2023-03-29 Sequenom, Inc. Verfahren und prozesse zur nichtinvasiven beurteilung genetischer variationen
MX357392B (es) 2012-04-02 2018-07-06 Berg Llc Ensayos basados en interrogatorios celulares y uso de los mismos.
SG10201607371UA (en) 2012-04-20 2016-10-28 Merus Nv Methods and means for the production of ig-like molecules
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
US9920361B2 (en) 2012-05-21 2018-03-20 Sequenom, Inc. Methods and compositions for analyzing nucleic acid
WO2014011928A1 (en) 2012-07-13 2014-01-16 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
US10662477B2 (en) 2012-10-01 2020-05-26 Millennium Pharmaceuticals, Inc. Biomarkers and methods to predict response to inhibitors and uses thereof
EP2909341A2 (de) 2012-10-18 2015-08-26 Oslo Universitetssykehus HF Biomarker für gebärmutterhalskrebs
CN104768579A (zh) 2012-10-23 2015-07-08 昂科梅德制药有限公司 使用Wnt途径结合剂来治疗神经内分泌肿瘤的方法
CA2890207A1 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
US10980804B2 (en) 2013-01-18 2021-04-20 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
EP2950885B1 (de) 2013-02-04 2018-11-21 Oncomed Pharmaceuticals, Inc. Verfahren und überwachung einer behandlung mit einem wnt-pfad-hemmer
AU2014223548A1 (en) 2013-02-26 2015-10-15 Triact Therapeutics, Inc. Cancer therapy
EP4202441A3 (de) 2013-03-09 2023-07-26 Immunis.AI, Inc. Genexpressionsprofil in makrophagen zur diagnose von krebs
EP3385717A3 (de) 2013-03-09 2018-10-24 Harry Stylli Verfahren zum nachweis von prostatakrebs
WO2014168711A1 (en) 2013-03-13 2014-10-16 Sequenom, Inc. Primers for dna methylation analysis
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
AU2014290044B2 (en) 2013-07-17 2020-10-29 Foundation Medicine, Inc. Methods of treating urothelial carcinomas
CA2923667A1 (en) 2013-09-09 2015-03-12 Triact Therapeutics, Inc. Cancer therapy
WO2015063604A2 (en) 2013-11-01 2015-05-07 Imberti Luisa BIOMARKERS PREDICTIVE OF THERAPEUTIC RESPONSIVENESS TO IFNβ AND USES THEREOF
EP3068882A2 (de) 2013-11-13 2016-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Kits von teilen mit nukleinsäuren mit fähigkeit zur bildung eines kissing-komplexes und verwendungen davon
ES2818823T3 (es) 2014-02-27 2021-04-14 Biogen Ma Inc Método de evaluación del riesgo de LMP
EP3736344A1 (de) 2014-03-13 2020-11-11 Sequenom, Inc. Verfahren und prozesse zur nichtinvasiven beurteilung genetischer variationen
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015172083A1 (en) 2014-05-08 2015-11-12 Biogen Ma Inc. Dimethylfumarate and prodrugs for treatment of multiple sclerosis
EP3143399A1 (de) 2014-05-12 2017-03-22 Biogen MA Inc. Biomarker zur vorhersage des fortschreitens von lupus und verwendungen davon
WO2016040843A1 (en) 2014-09-11 2016-03-17 Harry Stylli Methods of detecting prostate cancer
EP3191578B1 (de) 2014-09-12 2020-11-04 Whitehead Institute for Biomedical Research Zellen zur expression von apolipoprotein e und verwendungen davon
US10774388B2 (en) 2014-10-08 2020-09-15 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
JP2017537084A (ja) 2014-11-12 2017-12-14 トラコン ファーマシューティカルズ、インコーポレイテッド 抗エンドグリン抗体及びその用途
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
EP3314257B1 (de) * 2015-06-26 2021-06-16 Life Technologies Corporation Zellverfolgungsreagenzien und deren verfahren zur verwendung
WO2017040930A2 (en) 2015-09-03 2017-03-09 The Trustees Of The University Of Pennsylvania Biomarkers predictive of cytokine release syndrome
WO2017079572A1 (en) 2015-11-04 2017-05-11 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having multiple myeloma
CA3006743A1 (en) 2015-12-03 2017-06-08 Agios Pharmaceuticals, Inc. Mat2a inhibitors for treating mtap null cancer
TWI659751B (zh) 2017-01-13 2019-05-21 中央研究院 用以治療腦部疾病之可重複裝載之改良水膠系統
WO2018130660A1 (en) 2017-01-13 2018-07-19 Academia Sinica Reloadable hydrogel system for treating myocardial infarction
EP3599843A4 (de) 2017-03-24 2021-01-13 The Regents of the University of California Proteoglycan-irregularitäten in abnormalen fibroblasten und darauf basierende therapien
WO2019103967A1 (en) 2017-11-22 2019-05-31 The Regents Of The University Of Michigan Compositions and methods for treating cancer
WO2019109016A1 (en) 2017-12-01 2019-06-06 Millennium Pharmaceuticals, Inc. Biomarkers and methods for treatment with nae inhibitors
WO2019213619A1 (en) 2018-05-04 2019-11-07 Abbott Laboratories Hbv diagnostic, prognostic, and therapeutic methods and products
CN114088673B (zh) * 2021-11-15 2023-06-20 华南农业大学 一种光电电极、双模便携式传感器及其应用
WO2023135485A1 (en) 2022-01-13 2023-07-20 Oslo Universitetssykehus Hf Prostate cancer markers and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4174384A (en) * 1975-06-30 1979-11-13 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4822733A (en) * 1985-05-28 1989-04-18 Amoco Corporation Lifetime-resolved assay procedures
DE3786037T2 (de) * 1986-04-25 1993-11-25 Abbott Lab Tracer zur Benutzung in immunologischen Fluoreszenz-Polarisationsverfahren zum Nachweis von Flecainid.
US4777128A (en) * 1986-05-27 1988-10-11 Ethigen Corporation Fluorescence immunoassay involving energy transfer between two fluorophores
GB8820887D0 (en) * 1988-09-06 1988-10-05 Atomic Energy Authority Uk Detecting selected species

Also Published As

Publication number Publication date
JPH0666802A (ja) 1994-03-11
US5631169A (en) 1997-05-20
EP0552108B1 (de) 1999-11-10
JP3325939B2 (ja) 2002-09-17
CA2087413A1 (en) 1993-07-18
EP0552108A3 (en) 1993-09-22
DE69326967T2 (de) 2000-06-15
EP0552108A2 (de) 1993-07-21

Similar Documents

Publication Publication Date Title
DE69326967D1 (de) Phasenmodulationsenergieübertragungsfluoroimmunassay
DE69613660D1 (de) Energiesparende Phasenregelkreisschaltung
DE69316711D1 (de) Leistungswandler
FI931699A (fi) Artificiellt intelligent trafikmodel- och prediktionssystem
DE69316260T2 (de) Energieversorgungssystem
DE59301584D1 (de) Halbbrückenanordnung
DE69324107T2 (de) Dreiphasen-Leistungsanalysator
DE69313040D1 (de) Tragetaschen
DE69229262T2 (de) Wärmetransferklebstoff
DE69310584D1 (de) Leistungsregelung
DE69430939T2 (de) Intelligentes Leistungsbauelement
DE69224634D1 (de) Wasserwellenenergieumsetzer
DE69323261D1 (de) Phasenkontinuierlicher Modulator
DE69206613D1 (de) Frequenzmodulierter Schaltnetzteil.
DE59304586D1 (de) Induktor
DE69320959D1 (de) Energieregler
DE69330223D1 (de) Ladungsverschiebeanordnung
DE59302389D1 (de) Stromwandler
DE69314597D1 (de) Variabler Hochfrequenzleistungsverteiler
NO921069D0 (no) Energiutnyttelse
KR920018898U (ko) 소형 동력 흡충기
ITMI931389A0 (it) Assorbitore piatto
NO914693D0 (no) Energihjul
SE9202604D0 (sv) Kaskadutnyttjande av solenergi
SE9200861D0 (sv) Solcell

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee